Immunosuppressive drugs and fetal outcome
Abbreviated Journal Title
Best Pract. Res. Clin. Obstet. Gynaecol.
transplantation; pregnancy; immunosuppression; fetus; ORGAN TRANSPLANT RECIPIENTS; MYCOPHENOLIC-ACID PRODUCTS; RENAL-ALLOGRAFT; RECIPIENTS; PREGNANCY OUTCOMES; CYCLOSPORINE; KIDNEY; EXPOSURE; AZATHIOPRINE; EVEROLIMUS; SIROLIMUS; Obstetrics & Gynecology
Successful pregnancies have been reported in all types of solidorgan transplant recipients on a variety of immunosuppressive regimens. Immunosuppression is essential to maintain the transplanted organ and maternal health, thus the safety of these medications continues to be studied. This article reviews information in the literature and data from the National Trans-, plantation Pregnancy Registry (NTPR) in the United States related to immunosuppressive medication and pregnancy. Although most maintenance immunosuppressive regimens have not been shown to affect the outcome of posttransplant pregnancies, mycophenolic acid products are associated with an increased incidence of spontaneous abortion and an increase in the incidence and a specific pattern of birth defects. When counseling transplant recipients about the prospect and safety of pregnancy, the health of the mother, her graft, and the developing fetus must all be taken into account. (C) 2014 Elsevier Ltd. All rights reserved.
Best Practice & Research Clinical Obstetrics & Gynaecology
"Immunosuppressive drugs and fetal outcome" (2014). Faculty Bibliography 2010s. 5199.